Neogenomics (NEO) Accumulated Expenses (2010 - 2026)

Neogenomics (NEO) has reported Accumulated Expenses for 17 consecutive years, with $56.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 15.87% year-over-year to $56.3 million; the trailing twelve-month figure through Jun 2026 stood at $56.3 million (up 15.87% YoY), and the FY2025 full-year result was $47.6 million, down 23.8% from the prior year.
• Accumulated Expenses advanced to $56.3 million in Q2 2026 per NEO's latest filing, from $40.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $62.4 million in Q4 2024 and bottomed at $32.3 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $45.1 million across 5 years, with a median of $46.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 36.83% in 2022, then fell 23.8% in 2025.
• Over 5 years, Accumulated Expenses stood at $40.1 million in 2022, then surged by 32.44% to $53.2 million in 2023, then gained by 17.46% to $62.4 million in 2024, then declined by 23.8% to $47.6 million in 2025, then gained by 18.25% to $56.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $56.3 million, $40.6 million, and $47.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.